Catalog No.
Product Name
Application
Product Information
Citations
-
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-8 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. This compound promotes apoptosis in HCT-116 cells and effectively induces cell cycle arrest at the G1/S phase. It serves as a valuable tool for researchers investigating the roles of PI3K and mTOR signaling in cancer biology and potential therapeutic interventions. -
mTOR Inhibitor
YB-3-17 is a bifunctional PROTAC molecule that targets the mechanistic target of rapamycin (mTOR) with an IC50 of 0.22 nM and induces degradation of G1 to S phase transition 1 gene (GSPT1) with a DC50 of 5 nM. This compound demonstrates significant antiproliferative effects in various glioblastoma cell lines, achieving nanomolar IC50 values. Additionally, YB-3-17 exhibits notable antitumor efficacy in preclinical mouse models, making it a valuable tool for studying mTOR inhibition and its implications in cancer therapy. -
mTOR Inhibitor
CC214-1 is a potent mTOR inhibitor with an IC50 of 0.002 μM that induces autophagy. This compound serves as a valuable in vitro tool for investigating mTOR kinase biology. CC214-1 is particularly relevant for research in glioblastoma, providing insights into cancer cell metabolism and potential therapeutic strategies. -
mTOR-C1 Inhibitor
LGB321 is a selective mTOR-C1 inhibitor that effectively disrupts PIM2-dependent signaling pathways in multiple myeloma cell lines. This compound inhibits cell proliferation and modulates key cellular processes, including the phosphorylation of BAD. LGB321 is valuable for research focused on understanding the mechanisms of multiple myeloma and the mTOR signaling pathway. -
PI3K/mTOR Inhibitor
PI3K/mTOR-IN-18 is a highly selective dual inhibitor targeting PI3Kα and mTOR, with binding affinities of Ki=0.130 nM and Ki=0.111 nM, respectively. This compound effectively blocks the PI3K/AKT/mTOR signaling pathway, resulting in significant inhibition of tumor cell proliferation (IC50=144 nM). PI3K/mTOR-IN-18 is suitable for research involving various solid tumors, including breast cancer and non-small cell lung cancer (NSCLC). -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-14 is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), exhibiting IC50 values of 171.4 nM and 10.1 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its inhibition of the PI3K/mTOR signaling pathway can be critical for studies focused on cell proliferation and survival in various cancer models. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent dual inhibitor targeting the PI3K and mTOR pathways. It demonstrates a 4.7-fold increased potency compared to the positive control gedatolisib, with an IC50 of 0.3 μM. At a concentration of 10 μM, PI3K/mTOR Inhibitor-7 effectively suppresses the PI3K/Akt/mTOR signaling pathway. This compound is valuable for research applications focused on cancer biology and related therapeutic development. -
mTOR Inhibitor
mTOR inhibitor-18 is a selective inhibitor of the mechanistic target of rapamycin (mTOR). It exhibits significant activity in modulating intracellular signaling pathways associated with cell growth, proliferation, and survival. This compound is particularly useful in researching various conditions, including cancer, immune disorders, cardiovascular diseases, viral infections, inflammation, and metabolic or endocrine function disorders. Its role in neurological research further highlights its versatility as a critical tool in understanding mTOR-related biological processes. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-6 is a potent dual inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. This compound demonstrates enhanced stability in artificial gastric fluids compared to other PI3K/mTOR inhibitors. At a concentration of 10 μM, PI3K/mTOR Inhibitor-6 effectively suppresses the PI3K/Akt/mTOR signaling pathway, highlighting its potential for cancer research applications. -
mTOR Inhibitor
P-2281 is an mTOR inhibitor that exhibits significant anticancer and anti-inflammatory properties. It effectively inhibits mTOR activity in colon cancer cells and suppresses Dextran sulfate sodium salt (DSS)-induced colitis by modulating T cell function. P-2281 has demonstrated efficacy in murine models of human colitis, making it a valuable tool for research into cancer therapies and inflammatory bowel diseases. -
PI3K/mTOR Inhibitor
CC-M-1 is a potent and selective inhibitor of the PI3K/mTOR signaling pathway, targeting PI3Kα/β/γ/δ and mTOR with IC50 values of 0.68, 1.02, 1.03, 8.03, and 15 nM, respectively. This compound demonstrates significant inhibition of proliferation in colorectal cancer cell lines, including HCT-116 (IC50 = 0.38 μM) and HT-29 (IC50 = 1.70 μM). CC-M-1 serves as a valuable tool for researchers investigating colorectal cancer (CRC) therapeutic strategies and the underlying mechanisms of tumorigenesis. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-13 is a potent, orally active dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). This compound demonstrates significant biological activity against various pathologies, including solid tumors, sexual diseases, and idiopathic pulmonary fibrosis (IPF). It serves as a valuable tool for cancer research and therapeutic development related to these conditions. -
mTOR Inhibitor
mTOR inhibitor-13 is a selective inhibitor of mammalian target of rapamycin (mTOR) with an IC50 value of 0.29 nM, demonstrating potent inhibition. Additionally, this compound exhibits activity against PI3K-α with an IC50 of 119 nM. It is primarily utilized in research applications related to cancer, metabolic disorders, and cellular growth regulation, making it a valuable tool for investigating mTOR-mediated pathways. -
mTOR Inhibitor
mTOR inhibitor-17 is a selective inhibitor of the mechanistic target of rapamycin (mTOR), exhibiting an IC50 of 0.68 nM. This compound effectively inhibits cell proliferation in LNCaP prostate cancer cells with an IC50 of 40 nM. It is utilized in research to investigate the role of mTOR signaling in cancer metabolism and therapy. -
mTORC1 Inhibitor
mTORC1-IN-2 is an inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1). This compound functions by upregulating the expression of TSC2-P while concurrently inhibiting mTORC1 signaling. It exhibits vasodilatory effects and offers protection against myocardial hypoxic injury, making it a valuable tool for research in cardiovascular and metabolic disorders. Its impact on mTORC1 signaling pathways underscores its potential in studies related to cellular growth, proliferation, and survival. -
mTOR Inhibitor
mTOR inhibitor-24 (compound 9d) is a potent mTOR inhibitor, exhibiting an IC50 of 0.34 nM against mTOR and 324 nM against PI3K-α. This compound effectively inhibits the proliferation of LNCaP cells with an IC50 of 180 nM. It serves as a valuable tool for research in cancer biology and therapeutic exploration targeting the mTOR signaling pathway. -
mTOR Inhibitor
PF-06465603 is a potent and selective ATP-competitive inhibitor targeting the mTOR pathway. This compound serves as a valuable research tool for studying the regulation of cell growth, proliferation, and survival through mTOR signaling. As a metabolite of PF-04691502, PF-06465603 features a terminal carboxylic acid structure, further facilitating investigations into its biological activity and therapeutic potential in various diseases, including cancer and metabolic disorders. -
mTOR Inhibitor
mTOR inhibitor-16 (Compound 9f) is a selective inhibitor of the mechanistic target of rapamycin (mTOR). It demonstrates potent inhibitory activity against mTOR and PI3K-α, with IC50 values of 1.25 nM and 82 nM, respectively. This compound effectively inhibits the proliferation of LNCaP prostate cancer cells, with an IC50 of 140 nM, making it a valuable tool for cancer research and studies involving the mTOR signaling pathway. -
mTOR-DEPTOR Inhibitor
NSC126405 is an mTOR-DEPTOR inhibitor that disrupts the interaction between mTOR and DEPTOR, leading to enhanced cytotoxicity in multiple myeloma cells. This compound serves as a valuable tool in cancer research, allowing for the exploration of mTOR signaling pathways and potential therapeutic strategies in hematological malignancies. -
PI3K/mTOR Inhibitor
WJD008 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), specifically targeting PI3K α and mTOR kinase activities. It exhibits significant antiproliferative and anticlonogenic effects in tumor cells, particularly those with PIK3CA mutations. By disrupting the insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling pathway, WJD008 holds promise for advancing cancer research and therapeutic strategies. -
mTOR Inhibitor
mTOR inhibitor-10 (Compound 9c) is a selective inhibitor targeting the mechanistic target of rapamycin (mTOR). This compound effectively inhibits both mTOR and PI3K-α, demonstrating IC50 values of 0.7 nM and 825 nM, respectively. mTOR inhibitor-10 exhibits significant anti-proliferative activity against LNCaP cancer cells, with an IC50 value of 87 nM, making it a valuable tool for research in cancer biology and therapeutic applications. -
mTORC2 Inhibitor
JR-AB2-011 is a selective inhibitor of the mTORC2 complex, exhibiting an IC50 value of 0.36 μM. This compound disrupts the association between Rictor and mTOR (Ki: 0.19 μM), leading to reduced phosphorylation of Akt and decreased MMP2 activity. Consequently, JR-AB2-011 inhibits the migratory and invasive capabilities of tumor cells while also triggering non-apoptotic cell death. It serves as a valuable tool for research into cancer treatment and the regulation of cellular signaling pathways. -
mTORC1 Inhibitor
RMC-5552 is a potent and selective inhibitor of the mTORC1 pathway. It effectively inhibits the phosphorylation of S6K and 4EBP1 with IC50 values of 0.14 nM and 0.48 nM, respectively. RMC-5552 demonstrates significantly lower inhibition of AKT (IC50 of 19 nM), conferring a selectivity ratio for mTORC1 over mTORC2 of nearly 40-fold. This compound exhibits anti-cancer activity, making it a valuable tool for cancer research and therapeutic development targeting mTOR signaling. -
Rheb/mTORC1 Inhibitor
Rheb inhibitor NR1 is a selective Rheb/mTORC1 inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. This compound directly binds to the switch II domain of Rheb, effectively inhibiting the activation of the mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 attenuates phosphorylation of T389pS6K1 while enhancing phosphorylation of S473pAKT in a dose-dependent manner, with no effect on mTORC2 activity. It serves as a valuable tool for investigating the mTOR signaling pathway and its implications in various diseases. -
PIP4K2C-mTOR Activator
C24-Ceramide is a competitive binding agonist of PIP4K2C, a key regulator of the mTOR signaling pathway. This compound facilitates cellular processes such as enhanced keratinocyte proliferation and migration, thereby promoting skin wound healing. Moreover, C24-Ceramide has been implicated in the proliferation and metastasis of gallbladder cancer cells, indicating its potential as a therapeutic target. Additionally, C24-Ceramide levels in serum may serve as a diagnostic marker for gallbladder cancer. -
mTORC1 Activator
Mefluleucine hydrochloride is a selective and orally active activator of mTORC1, functioning primarily through its interaction with Sestrin2. This leucine analog plays a critical role in neurobiology and has been utilized in research studies focused on antidepressant mechanisms. Its distinct properties make it a valuable tool for investigating mTORC1 signaling pathways and their implications in mood disorders. -
mTORC1-Selective Inhibitor
RMC-6272 is a bi-steric inhibitor selectively targeting mTORC1. It demonstrates potent inhibition of mTORC1 with over 10-fold selectivity compared to mTORC2, outperforming Rapamycin in its ability to inhibit mTORC1 and induce cell death in TSC2 null tumors. This compound is valuable for research applications focusing on cancer biology and therapeutic strategies targeting the mTOR signaling pathway. -
Dual PI3K/mTOR Inhibitor
PKI-179 is a highly effective dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ, and mTOR, respectively. It demonstrates significant activity against E545K and H1047R mutant isoforms, with IC50 values of 14 nM and 11 nM. PKI-179 is utilized in cancer research due to its proven anti-tumor efficacy in vivo, making it a valuable tool for investigating the PI3K/mTOR signaling pathway in various cancer models. -
mTOR Inhibitor
PQR626 is a selective mTOR inhibitor that demonstrates potent activity with an IC50 of 5 nM and a Ki of 3.6 nM. This orally active compound is designed for effective brain penetration, making it suitable for investigating neurological disorders. Research applications include studying the role of mTOR in neurodegenerative diseases and evaluating potential therapeutic strategies targeting this pathway. -
mTORC1/mTORC2 Inhibitor
MTI-31 is a potent inhibitor of mTORC1 and mTORC2, demonstrating high selectivity for mTOR with a Kd of 0.20 nM and over 5,000-fold selectivity against PIK3CA, PIK3CB, and PIK3G. It exhibits an IC50 of 39 nM in the LANCE assay for mTOR substrate phosphorylation in the presence of 100 μM ATP. This compound is valuable for research into breast cancer and other diseases involving aberrant mTOR signaling pathways. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-4 is a potent orally active pan-class I PI3K/mTOR inhibitor. It demonstrates enzymatic inhibition across PI3Kα, PI3Kγ, PI3Kδ, and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM, and 13.85 nM, respectively. This reagent is primarily utilized in cancer research to investigate the role of the PI3K/mTOR signaling pathway in tumorigenesis and therapeutic responses. -
mTOR Inhibitor
WYE-23 is a selective mTOR inhibitor with a reported IC50 of 0.45 nM against mTOR and 661 nM against PI3Kα. This compound exhibits significant antitumor activity, making it a valuable reagent for cancer research. It is particularly useful for studies investigating the role of mTOR signaling in tumorigenesis and therapeutic interventions targeting this pathway. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-11 is a potent oral inhibitor of the PI3K/mTOR signaling pathway, exhibiting IC50 values of 3.5 nM, 4.6 nM, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR, respectively. This compound effectively impairs the phosphorylation of AKT and S6 proteins, thereby modulating critical cellular processes. PI3K/mTOR Inhibitor-11 is valuable for cancer research, offering insights into therapeutic strategies targeting aberrant signaling in tumors. -
mTORC1 Inhibitor
RMC-4627 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of cell growth and proliferation. This compound has been shown to activate 4EBP1, leading to the downregulation of protein synthesis and subsequently inhibiting tumor growth. RMC-4627 is valuable for research applications focused on cancer biology and the elucidation of mTOR signaling pathways. -
TMBIM6 Antagonist
TMBIM6 antagonist-1 selectively inhibits TMBIM6, disrupting its interaction with mTORC2, and thereby decreasing mTORC2 activity. This compound also modulates TMBIM6-mediated calcium leakage, which is relevant for investigating calcium signaling pathways. TMBIM6 antagonist-1 serves as a valuable tool for research on cellular signaling and the role of TMBIM6 in various biological processes. -
mTOR Complex 1 Inhibitor
WRX606 is a selective inhibitor of the mTOR complex 1 (mTORC1), which effectively disrupts the phosphorylation of key mTORC1 substrates, including S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E binding protein (4E-BP1), with IC50 values of 10 nM and 0.27 μM, respectively. This compound demonstrates significant antitumor activity by suppressing tumor growth in mouse models without promoting metastasis. WRX606 is a valuable tool for research focused on exploring therapeutic strategies against cancer through mTORC1 inhibition. -
mTOR Inhibitor
mTOR inhibitor WYE-28 selectively targets the mammalian target of rapamycin (mTOR), exhibiting an IC50 of 0.08 nM. Additionally, it inhibits PI3Kα with an IC50 of 6 nM, demonstrating its potential for broader applications in cancer therapy and metabolic research. WYE-28 has a metabolic half-life (T1/2) of 13 minutes in nude mouse microsomes, making it a valuable reagent for studying mTOR signaling pathways and their implications in disease models. -
mTOR Inhibitor
(32-Carbonyl)-RMC-5552 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), effectively blocking mTORC1 and mTORC2 signaling pathways. This compound impedes the phosphorylation of key substrates including p-P70S6K-(T389), p-4E-BP1-(T37/36), and p-AKT1/2/3-(S473), with pIC50 values greater than 9 for the first two and between 8 and 9 for the latter. (32-Carbonyl)-RMC-5552 is valuable for studies investigating mTOR-related cellular processes and the development of therapies targeting mTOR in various diseases. -
mTORC1/2 Inhibitor
AZD3147 is a potent, orally bioavailable dual inhibitor of mTORC1 and mTORC2, exhibiting an IC50 value of 1.5 nM. This compound selectively targets both complexes, while also having a specific inhibitory effect on PI3K. AZD3147 is primarily utilized in research related to cancer therapeutics and metabolic disorders, where modulation of the mTOR signaling pathway is of significant interest. -
mTOR Inhibitor
WYE-687 dihydrochloride is an ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR), demonstrating an IC50 of 7 nM. This compound effectively inhibits the activation of both mTORC1 and mTORC2, making it a valuable tool for studying mTOR signaling pathways. Additionally, WYE-687 modulates PI3Kα and PI3Kγ activity with IC50 values of 81 nM and 3.11 μM, respectively, supporting its role in cancer and metabolic research. -
Nrf2/AMPK/mTOR Activator
Hydroxycitric acid (tripotassium) is a potent activator of the Nrf2, AMPK, and mTOR signaling pathways. It enhances the expression of antioxidant enzymes, elevates glutathione levels, and inhibits ferroptosis, thereby providing protection against oxidative stress and promoting cellular health. This compound is actively engaged in regulating renal and pulmonary vascular functions and is also implicated in the induction of apoptosis in cancer cells through cell cycle arrest and DNA fragmentation. Its multi-target bioactivity makes it a valuable tool in research focused on oxidative stress, cancer biology, and metabolic regulation. -
PI3K/mTOR Inhibitor
NVP-BBD130 is a potent dual inhibitor of PI3K and mTOR, functioning through ATP-competitive mechanisms. This compound demonstrates significant stability and provides effective oral bioavailability. Additionally, NVP-BBD130 serves as a click chemistry reagent due to its alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its versatility makes it suitable for various research applications in cancer therapy and biochemical signaling pathways.
